Proffered Paper - Non-metastatic NSCLC and other thoracic malignancies
LINK to STREAM (needs an ESMO registration)
1214O - Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)
The abstract concludes: Enrollment was stopped because of excessive 90-day postoperative mortality. Deaths were due to postoperative complications possibly related to comorbidities and not to direct durvalumab toxicity. MPR rates and ongoing correlative analyses will be presented.
Read also ESMO's Daily Reporter News:
1215O - Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): results from the phase II PRINCEPS trial.
The abstract concludes: Surgery after one infusion of A was safe. The short delay between A and surgery might explain the absence of MPR.
LBA84 - Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial
The abstract concludes: PFS for LS-SCLC pts is not found different between C and O, possibly due to the short period on active treatment observed in the study.
1783O - Patient reported outcomes from a randomized phase II trial comparing standard-dose with high-dose twice daily (BID) thoracic radiotherapy (TRT) in limited stage small cell lung cancer (LS SCLC)
The abstract concludes: